What Factors Propelled The Growth Of The Metered Dose Inhaler Devices Market In The Past?
The metered dose inhaler devices market has seen considerable growth due to a variety of factors.
• In recent years, there has been substantial growth in the market size for metered dose inhaler devices. The market is predicted to expand from $15.46 billion in 2024 to $16.36 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%.
This growth historically is due to factors such as a higher incidence of diabetes, increased reliance on metered dose inhaler devices, an amplified demand for these devices, and a rise in the prevalence of COPD.
What Are the Future Growth Projections for the Metered Dose Inhaler Devices Market?
The metered dose inhaler devices market is expected to maintain its strong growth trajectory in upcoming years.
• The market for metered dose inhaler devices is projected to see a significant surge in size in the forthcoming years. The forecast predicts it to reach $20.29 billion by 2029, boasting a compound annual growth rate (CAGR) of 5.5%.
This expected growth over the forecast period can be related to the growing cases of chronic obstructive pulmonary diseases, an increase in asthma incidents, higher incidence of infectious diseases, a rise in diabetes cases, and a surge in respiratory illnesses. Key movements in the forecast period encompass technological improvements, groundbreaking therapies, regulatory green lights, the invention of new inhalers, and the uptake of digital marketing methods.
What Are The Primary Growth Drivers In The Metered Dose Inhaler Devices Market?
The anticipated rise in chronic obstructive pulmonary diseases (COPD) incidence is predicted to spur the expansion of the metered dose inhaler devices market. COPD, a gradually advancing lung ailment, is characterized by blockage of airflow, usually triggered by long-term contact with irritants like cigarette smoke. This leads to symptoms such as breathlessness, coughing, and wheezing. Factors stimulating the rising prevalence of COPD include tobacco use, atmospheric pollution, aging societal demographics, and deferred diagnosis or therapy. Metered dose inhaler (MDI) devices aid in managing COPD by administering medication directly to the lungs, offering immediate relief and enhancing airflow. For example, a projection by the National Institutes of Health, a US-based governmental entity, in December 2023 stated that the number of COPD cases would increase from 532 million in 2030 to a total of 592 million by 2050. Consequently, the escalating occurrence of chronic obstructive pulmonary diseases is propelling the expansion of the metered dose inhaler devices market.
What Are The Major Segments Within The Metered Dose Inhaler Devices Market?
The metered dose inhaler devices market covered in this report is segmented –
1) By Type: Desktop Metered Dose Inhaler Devices, Portable Metered Dose Inhaler Devices, Other Types
2) By Distribution Channel: Online, Offline
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Other Applications
4) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices, High-performance desktop MDI devices, Smart desktop MDI devices
2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices, Advanced portable MDI devices, Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices, Dry powder inhaler (DPI) combined devices, Soft mist inhaler (SMI) devices, Other specialized MDI devices
Pre-Book The Metered Dose Inhaler Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Trends Are Expected To Transform The Metered Dose Inhaler Devices
Major firms in the metered dose inhaler devices market are honing their focus on the creation of more technologically advanced solutions. This includes the development of pressurized metered dose inhalers, which are intended to improve both drug delivery efficiency as well as patient compliance. Pressurized metered-dose inhalers, also known as pMDIs, are devices that supply medication in a measured aerosol form, propelled by pressure. As an example, in July 2023, an Indian pharmaceutical organization by the name of Lupin Limited rolled out Luforbec 100/6. This pMDI is purposed for the treatment of adult asthma as well as chronic obstructive pulmonary disease, or COPD, in Germany. The product brings together beclometasone (100 µg) and formoterol (6 µg), and in doing so, provides a robust solution for patients who need combination therapy. Notably, Luforbec's cost is about 47% less than the fixed reference price, which makes it more accessible. Given that about 5% of adults in Germany are affected by asthma, this rollout emphasizes Lupin's dedication to cater to crucial healthcare needs and better patient results in the field of respiratory care.
Who Are the Key Players in the Metered Dose Inhaler Devices Market?
Major companies operating in the metered dose inhaler devices market are include:
• Pfizer Inc.
• Merck & Co. Inc.
• AstraZeneca PLC
• GlaxoSmithKline plc
• 3M Company
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd.
• Berry Global Inc.
• AptarGroup Inc.
• Philips Healthcare
• Chiesi Farmaceutici S.p.A.
• Cipla Limited
• Gerresheimer AG
• Zydus Lifesciences Limited
• Mylan N.V.
• Nemera
• Beximco Pharmaceuticals Limited
• Cohero Health Inc.
• Bespak Europe Ltd.
• Trudell Medical International
• Iconovo AB
What Is The Most Dominant Region In The Metered Dose Inhaler Devices Market?
North America was the largest region in the metered dose inhaler devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
